Vikram Anand, president of compliance services at EVERSANA, has set out a vision for where pharmacovigilance infrastructure is headed next.
Anand’s remarks close out a series of conversations with Pharmaceutical Commerce focused on the operational realities behind drug safety systems.
In earlier installments, Anand examined how pharmacovigilance gaps contribute to complete response letters and the blind spots that cause them.
In this final segment, he shifts focus to what connected safety systems mean for physicians and patients affected by launch delays and drug safety failures.
Anand argues that a connected safety system transforms pharmacovigilance from a paperwork exercise into a predictive shield for the people who matter most.
That transformation enables faster signal detection, faster guidance to physicians, and faster action when safety concerns emerge in the field.
Physicians, Anand says, extend access to companies that behave as reliable partners and deliver safety information consistently and at the right time.
He traces how medical information teams, which field questions from healthcare professionals and patients through channels like medical inquiry lines, must work in close coordination with pharmacovigilance and quality teams.
When that coordination breaks down, adverse events and product complaints become siloed rather than surfacing quickly through the right channels.
When the handoff works as intended, Anand says it produces faster guidance, safer patients, and greater trust in the therapy being prescribed.
He points to full automation at the intake level as the next major phase for pharmacovigilance infrastructure across the industry.
Artificial intelligence and natural language processing, he explains, would extract adverse events from emails, scientific literature, and digital channels in place of manual review processes.
Anand connects this technological shift to the industry’s broader move toward personalized medicine, including cell and gene therapy treatments.
Small patient populations and long study timelines in these emerging therapeutic areas make the evolution toward automated, connected systems especially critical going forward.